Biohaven Pharmaceuticals announced that the FDA will not convene an advisory committee to evaluate its spinocerebellar ataxia drug, troriluzole, indicating regulatory clarity on its safety and efficacy profiles ahead of an expected decision later in the year. This development reduces regulatory uncertainty for Biohaven’s candidate. However, industry analysts note that pending verdicts bear scrutiny. Separately, Catalent announced workforce reductions at its Baltimore gene therapy site due to shifting customer demand, illustrating operational challenges facing contract manufacturers in the evolving gene therapy market.